[Interchangeability of biological products in the Brazilian Unified National Health System (SUS): the main regulatory challenges].

Biological products have sparked a worldwide therapeutic revolution. However, the high cost of these products threatens health systems' sustainability. The development of copies is considered an economic alternative, but due to the products' complexity, many concepts used in generic drugs do not apply.